Gawande looks to remove waste as he gears up to head healthcare initiative

After his  appointment as CEO of the new Amazon-Berkshire Hathaway-JPMorgan Chase healthcare venture, Atul Gawande, MD, stated the undertaking will look to target wasteful spending, while providing better outcomes and satisfaction and removing “some of the middlemen" from the system.

“My job for them is to figure out ways that we’re going to drive better outcomes, better satisfaction with care and better cost efficiency with new models that can be incubated for all,” Gawande said.

The venture is slated to target three types of waste in the healthcare system including administrative costs, high prices and “improper” healthcare usage, according to reporting from Bloomberg.com.

To read more, click the link below:

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.